Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Carboplatin Market 2020 and China Ovarian Cancer Treatment Drugs 2024 Forecasts in New Research Reports


News provided by

RnR Market Research

10 Jul, 2015, 06:00 GMT

Share this article

Share toX

Share this article

Share toX

DALLAS, July 10, 2015 /PRNewswire/ --

RnRMarketResearch.com adds new cancer drugs market research titled Global Carboplatin Industry Report 2015 and Ovarian Cancer Treatment Drugs Markets in China to the cancer drugs intelligence collection of its library.

Complete report on carboplatin market spread across 148 pages, talking about 8 major companies and supported with 172 tables and figures is now available at http://www.rnrmarketresearch.com/global-carboplatin-industry-report-2015-market-report.html .

The global carboplatin market report 2015 is a professional and in-depth study on the current state of the Carboplatin industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Carboplatin market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans of carboplatin market are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. The report focuses on global major leading industry players of carboplatin market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Carboplatin market development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

With 172 tables and figures to support carboplatin market analysis, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Companies profiled in this research include Hospira, Sagent, Teva, FRESENIUS KABI, Mylan, Actavis, Qilu and Hisun. Order a copy of global carboplatin market report 2015 research at http://www.rnrmarketresearch.com/contacts/purchase?rname=394829 .

Partial list of data tables and figures provided in the carboplatin market 2015 research report includes:

Figure Price Comparison of Global Carboplatin Key Manufacturers in 2015 (USD/Pcs)
Table US Capacity (K Pcs), Production (K Pcs), Price (USD/Pcs), Cost (USD/Pcs) and Revenue (M USD) of Carboplatin 2010-2015
Table EU Capacity (K Pcs), Production (K Pcs), Price (USD/Pcs), Cost (USD/Pcs) and Revenue (M USD) of Carboplatin 2010-2015
Table Japan Capacity (K Pcs), Production (K Pcs), Price (USD/Pcs), Cost (USD/Pcs) and Revenue (M USD) of Carboplatin 2010-2015
Table China Capacity (K Pcs), Production (K Pcs), Price (USD/Pcs), Cost (USD/Pcs) and Revenue (M USD) of Carboplatin 2010-2015

Table Market Share of Different Carboplatin Price Level
Table Gross Margin of Different Carboplatin Applications
Table Traders or Distributors of Carboplatin with Contact Information
Table Ex-work Price, Channel Price and End Buyer Price of Carboplatin (USD/Pcs)
Table Regional Import, Export, and Trade of Carboplatin (K Pcs)
Figure Global Capacity (K Pcs), Production (K Pcs) and Growth Rate of Carboplatin 2015-2020
Figure Global Capacity Utilization Rate of Carboplatin 2015-2020
Figure China Capacity (K Pcs), Production (K Pcs) and Growth Rate of Carboplatin 2015-2020
Figure China Capacity Utilization Rate of Carboplatin 2015-2020
Figure Global Production Market Share of Major Carboplatin Manufacturers in 2015
Figure Global Production Market Share of Major Carboplatin Manufacturers in 2020
Figure Production Market Share of China Major Carboplatin Manufacturers in 2015
Figure Production Market Share of China Major Carboplatin Manufacturers in 2020
Figure Global and China Sales (K Pcs) and Growth Rate of Carboplatin 2015-2020
Table Global Supply, Sales and Shortage of Carboplatin 2015-2020 (K Pcs)
Table China Supply, Sales and Shortage of Carboplatin 2015-2020 (K Pcs)
Table China Production, Import, Export and Consumption of Carboplatin 2015-2020 (K Pcs)
Table Global Production (K Pcs), Price (USD/Pcs), Cost (USD/Pcs), Revenue (M USD) and Gross Margin of Carboplatin 2015-2020
Table China Production (K Pcs), Price (USD/Pcs), Cost (USD/Pcs), Revenue (M USD) and Gross Margin of Carboplatin 2015-2020

The Ovarian Cancer Treatment Drugs Markets in China 2015 research report provides historical data (2004, 2009 and 2014) and long-term forecasts through 2019 and 2024 are presented. Major producers in China are profiled. It examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments' industry bureaus, industry publications, and our in-house databases. Interviews are conducted with Chinese industry experts, university professors, and producers in China. Economic models and quantitative methods are applied in this report to project market demand and industry trends. Metric system is used and values are presented in either Yuan (RMB, current price) and/or US dollars. Sales volumes and import information is provided for Chemotherapeutic Drug, Paclitaxel, Fluoropyrimidines, Anthracycline Antibiotics, Therapertic Antibody, Small Molecules Drug, Aromatase Inhibitors (Targeted Therapy Drug)Platinum Anticancer Drugs, Anti-Estrogens, Aromatase Inhibitors (Endocrine Therapy Drug) and Lh-Rh. Ovarian Cancer Treatment Drugs Producer Profiles and Directory is also covered in this research. Comprehensive table of contents and more on the 2015 report titled Ovarian Cancer Treatment Drugs Markets in China is available at http://www.rnrmarketresearch.com/chinese-markets-for-ovarian-cancer-treatment-drugs-market-report.html .

Explore more reports on the cancer drugs market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.